Please wait
Healthcare · Biotechnology · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
$25.2B
N/A
16.26
Current price
$123.22
-0.9% todayUpdated 2 min ago
Open
$127.74
Previous close
$124.37
Day range
$121.61 – $127.75
Volume
N/A
16.3x P/E
Awaiting filing
No current yield
65/100 measured
Easy to trade
Recent price movement, key market context and the latest company information.
The latest saved price history for INCY, with its range and direction at a glance.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Investors usually follow INCY for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 79/100 while there is no strong bear warning from the current data. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
$586M
TTM (2026-06-30)
ROE
30.7%
Return on equity
ROA
16.8%
Return on assets
Debt / equity
0.01
Lower is usually safer.
P/B ratio
3.94
Useful for book value support.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
$125.75
Analyst view
Buy
Analyst target
$127.13
Forecast refresh
Updated just now
Quality score
78
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+3.1% across the latest saved price window.
Volatility
Low
Beta is 0.77. Price has historically moved more calmly than the wider market.
52-week position
82% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
high_energy_costs
INCY may also move because the HEALTHCARE sector may move with high_energy_costs. Confidence 63%.
PMG-MAN stated the pharmaceutical sector spends a large share of revenue on energy, reducing competitiveness industry-wide.
policy_stability_and_support
INCY may also move because the HEALTHCARE sector may benefit from policy_stability_and_support. Confidence 60%.
The sector would benefit from extended Presidential Executive Order, dedicated energy tariffs, and policies encouraging local API production to attract investment and boost local manufacturing.
INCY
Incyte Corporation
Price: $123.22
P/E: 16.257517
Yield: N/A
ABBV
AbbVie Inc.
Price: $256.42
P/E: 72.994286
Yield: 2.7%
ABT
Abbott Laboratories
Price: $110.36
P/E: 36.39806
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: $159.79
P/E: 27.310226
Yield: 0.0%
Industry
Biotechnology
Employees
2844
Exchange
NMS
Ticker
INCY
